
Ep. 306 - Treg Inflection Point; Biotech's Next Big Story; Tax Bill Consequences
Treg-based cell therapies are nearing a clinical proof-of-concept inflection point, but in an environment that has dramatically shifted with the advent of CAR T therapies for autoimmune diseases. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what these cell therapies need to show to be relevant in the fast-changing I&I world, and which types of indications may best suit the cells’ unique profile.
The team also explores the biotech sector’s ongoing struggle to capture the interest of generalist investors, and what the next major theme might be to draw them back.
The analysts then break down the key provisions in the recently passed U.S. reconciliation tax bill, highlighting the positive and negative developments, as well as the missed opportunities for the industry. This episode of BioCentury This Week was sponsored by IQVIA Biotech.
View full story: https://www.biocentury.com/article/656376
#biotech #biopharma #pharma #lifescience #CellTherapy #TregTherapy #CAR_T
00:01 - Sponsor Message: IQVIA Biotech
01:19 - Treg Inflection Point
10:57 - Biotech's Next Big Story
22:36 - Tax Bill Consequences
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Weitere Episoden von „BioCentury This Week“
Verpasse keine Episode von “BioCentury This Week” und abonniere ihn in der kostenlosen GetPodcast App.